Rocket Lab’s $18M Insider Exodus Casts a Shadow Over a $2.2B Backlog and New Pentagon Wins

Rocket Lab USA finds itself at a sharp crossroads. The space infrastructure company is sitting on a record $2.2 billion order book, its Space Systems division is outgrowing the core launch business, and the US Space Force has just handed over a $90 million satellite contract. Yet inside the C-suite, the atmosphere tells a different story: four executives have cashed out nearly $18 million in stock during the recent rally, and not a single insider has bought shares in the past twelve months.

The selling spree, disclosed in regulatory filings, comes right as Stifel analyst Erik Rasmussen lifted his price target to $132 — the highest on Wall Street — while maintaining a buy rating. That stark contrast between insider profit-taking and analyst optimism is fueling a nervous reconsideration of the stock.

The $18 Million Unwind

Director Alexander R. Slusky led the sell-off with two transactions. On June 2, he disposed of 40,000 shares at $123.60 each, raising $4.944 million. A second trade saw 60,000 shares change hands for $8.964 million. After that, Slusky still held 334,675 shares indirectly through Abalone Cove LLLP and another 61,331 shares directly.

President Marvin Bradford Clevenger joined the selling, offloading 3,500 shares for $513,345. Chief Operating Officer Frank Klein and Chief Legal Officer Arjun Kampani also exited positions, both under pre-arranged 10b5-1 trading plans. The cumulative total across all four executives came to roughly $18 million.

The pattern is jarring: over the trailing twelve months, Rocket Lab has recorded 116 insider sales and zero insider purchases. While such imbalances are not automatically bearish — executives often diversify for personal reasons — the timing clashes with the loud bullishness emanating from Wall Street.

Analysts Double Down

Rasmussen’s revised $132 target, up from $110, rests on a concrete operational story. The Electron rocket has matured into a scalable business with higher utilization rates driving margins. The Space Systems segment brings multiyear government contracts that add predictable revenue. And the untapped catalyst remains Neutron, the company’s medium-lift reusable rocket, which Stifel sees as the key to a further valuation rerating.

Rasmussen’s track record strengthens his call. On TipRanks, he ranks 117th out of more than 12,200 analysts, placing him in the top 1% of forecasters.

The broader analyst consensus mirrors that confidence. This month alone, Rocket Lab scores 15 buy ratings, four holds, and zero sells. Yet that uniformity hasn’t prevented the stock from suffering its worst single-day sell-off in over two years.

Macro Headwinds Dampen the Rally

The catalyst for that rout came from outside the company. On Friday, Rocket Lab shares tumbled 8.2%, dragged down by rising bond yields and a rotation out of long-duration growth names. The US jobs report for May showed 172,000 new positions, up from 115,000 a month earlier, dashing hopes for an imminent Federal Reserve rate cut and sending yields higher.

Should investors sell immediately? Or is it worth buying Rocket Lab USA?

Intraday on June 8, the stock oscillated between $106.73 and $122.50, closing at $107.60 — roughly 12.2% below the session high. That volatility underscores how quickly buying enthusiasm evaporates in the current rate environment.

For the week, Rocket Lab gave up 10%, finishing at $110.08. Even so, the year-to-date gain remains a robust 45%, and the 12-month return stands at a stunning 271%. The 50-day moving average sits near $96, a level that, if held, keeps the longer-term uptrend intact.

Backlog and Backbone

Operationally, the growth story is intact and accelerating. First-quarter 2026 revenue hit $200.3 million, a 63.5% year-over-year surge. The backlog expanded 20% sequentially and 108% from a year ago to roughly $2.2 billion. Management has guided for $225 million to $240 million in second-quarter revenue.

An increasing share of that revenue comes from Space Systems — spacecraft components like star trackers and solar panels, plus full satellite builds. The US Space Force contract awarded this spring epitomizes the shift: for $90 million, Rocket Lab will build and operate two satellites carrying the Heimdall payload for space surveillance, cracking a market long dominated by traditional prime contractors.

The launch side remains active too. On June 10, the company is set to fly the “Curveball” mission using the HASTE rocket from Virginia’s spaceport, a vehicle dedicated to hypersonic technology testing for the Department of Defense.

Meanwhile, Neutron’s first flight is slated for the second half of 2026, with production ramping in Virginia. If executed on schedule, Neutron would open the door to deploying large satellite constellations, a capability that would fundamentally alter Rocket Lab’s addressable market.

Institutional Appetite Versus Insider Caution

Institutional investors are taking sides. In the most recent quarter, 541 funds increased their stakes while 363 reduced exposure — hardly a wholesale retreat, but evidence of a heated debate over fair value.

The company continues to burn cash and post net losses, and execution risk around Neutron remains high. That is the rub: the stock has priced in a future where the backlog converts to profitable growth and Neutron flies on time, but the insider selling suggests those at the table are less certain than the analysts cheering from the sidelines. Until Rocket Lab delivers tangible proof — in margins, in Neutron milestones, in sustained institutional buying — the gap between euphoria and skepticism will remain the defining force behind the stock’s swings.